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As vaccine manufacturers tackle increasingly intractable 
pathogens, vaccines will be developed that show eﬃ  cacy, 
but that are less eﬃ  cacious than established vaccines. 
Consequently, regulatory and public health authorities will 
be faced with diﬃ  cult decisions about whether such vaccines 
should be recommended for implementation and, if so, 
under what circumstances. The RTS,S/AS01 malaria candidate 
vaccine provides an important example of such a challenge.
After a long period of development,1,2 a large 
phase 3 trial3 of RTS,S/AS01 in children aged 5–17 months 
at ﬁ rst vaccination showed a vaccine eﬃ  cacy of 28·3% 
(95% CI 23·3–32·9%) against clinical malaria in children 
who received three doses, and of 36·3% (31·8–40·5%) in 
those given a fourth dose, during 48 months of follow-up. 
The vaccine also provided signiﬁ cant protection against 
severe malaria and hospital admissions in the group of 
children who received a fourth dose.3 An average of 1774 
cases (95% CI 1387–2186) of clinical malaria were averted 
per 1000 children vaccinated in the four-dose group. 
An unexplained increase in incidence of meningitis was 
identiﬁ ed as a safety signal. Eﬃ  cacy was lower in infants 
who received their ﬁ rst dose of vaccine aged 6–12 weeks 
than in children aged 5–17 months. Could this vaccine with 
restricted eﬃ  cacy still have a useful role in malaria control? 
In The Lancet, Melissa Penny and colleagues4 provide some 
important new information that suggests that it could.
Four modelling groups have worked together to 
estimate the potential impact of RTS,S/AS01 on malaria 
cases and deaths. Overall, the models gave similar results. 
On the basis of assumptions of 72% coverage with a 
four-dose schedule, a 15 year follow-up period (needed 
to account for any age shift in malaria incidence), and a 
vaccine price of US$2–10 per dose, the models predicted 
that in the areas where the parasite prevalence in children 
aged 2–10 years (PfPR2–10; a widely used measure of the 
intensity of malaria transmission) lies between 10% 
and 65%, RTS,S/AS01 would prevent 116 480 (range 
31 450–160 410) cases of clinical malaria and 484 
(190–860) deaths per 100 000 fully vaccinated children. 
At $5 a dose, the cost per disability-adjusted life-year 
(DALY) averted in areas with a PfPR2–10 of 10% or more 
would be less than $100, an amount comparable to that 
of other malaria control measures.3 As recognised by 
the investigators, the study includes several unproven 
assumptions. The most important of these is the 
assumption that RTS,S/AS01 will have a signiﬁ cant impact 
on mortality, a key factor for decision makers and for 
calculation of DALYs; this assumption is not yet supported 
by empirical data. However, the quality of care provided to 
children in trials of RTS,S/AS01 was exemplary and, in the 
phase 3 trial, mortality was very low in all study groups.5 
Trials of seasonal malaria chemoprevention also failed to 
show a statistically signiﬁ cant impact on mortality,6 but 
this intervention is having a major impact when deployed 
on a large scale. By contrast, trials of insecticide-treated 
nets did show an impact on mortality,7 but these studies 
were done at the community level, with less intensive 
follow-up of individual participants. The assumption that 
RTS,S/AS01 will have a signiﬁ cant impact on mortality if 
deployed in high transmission areas is a reasonable one.
The European Medicines Agency reviewed the eﬃ  cacy 
and safety of RTS,S/AS01 and, under article 58, gave 
a positive opinion on its use in both the younger and 
older age groups included in the phase 3 trial.8 By 
contrast, WHO’s Strategic Advisory Group of Experts on 
Immunization and Malaria Policy Advisory Committee 
only recommended use of the vaccine in children in 
the older age group.9 They also recommended that 
several pilot studies should be undertaken before 
widespread deployment of the vaccine. The objective of 
these pilot projects would be to assess whether routine 
immunisation programmes can deliver the four-dose 
schedule eﬀ ectively, whether the vaccine prevents deaths, 
and whether the safety signals detected in the phase 3 
trial were just chance ﬁ ndings. To abandon RTS,S/AS01 at 
this point would be a major setback in the endeavour 
to develop a malaria vaccine, in addition to vaccines 
against other infections present mainly in low-income 
countries, and a discouragement to major pharmaceutical 
companies and public–private partnerships to engage in 
these activities. Therefore, these pilot programmes must 
move forward quickly, should be large enough to evaluate 
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The migration crisis is one of the most pressing global 
challenges, as worldwide displacement is now at the 
highest level ever recorded. Latest global estimates by 
the UN Commissioner for Refugees (UNHCR) show that 
59·5 million people are forcibly displaced as a result of 
persecution, conﬂ ict, generalised violence, or human 
rights violations.1 The estimated refugee population 
reached an unprecedented 19·6 million individuals 
worldwide in 2015—half of them being children—and 
the number is steadily increasing, with Syria as the 
leading country of origin of refugees.1,2 A lengthy drought 
preceded the Syrian crisis that led to a large movement 
of people into cities and contributed to instability; recent 
evidence suggests that risks of such droughts in the region 
are more than doubled as a result of climate change.3 
More than a million refugees and migrants arrived in the 
European Union in 2015.4 The growing inﬂ ux of vulnerable 
populations poses many challenges to host countries, not 
least with regard to preparedness and resilience of health 
systems and access to health-care services. Furthermore, 
increasing numbers of refugees are likely in future as a 
result of a complex combination of driving forces, such 
as faltering and unequal economic growth, population 
increases, conﬂ icts, and environmental change. The need 
to develop more eﬀ ective approaches that respond to the 
health needs of displaced populations and address the 
root causes of displacement is therefore imperative.
A refugee is someone who “owing to a well-founded 
fear of being persecuted for reasons of race, religion, 
nationality, membership of a particular social group 
or political opinion, is outside the country of his 
nationality, and is unable to, or owing to such fear, 
is unwilling to avail himself of the protection of 
that country”.5 Refugees experience conditions of 
vulnerability, marginalisation, and poverty, in addition 
to the high stress of displacement, which seriously aﬀ ect 
the health of these populations, including women, 
children, and older people.
Evidence suggests that refugees often have acute 
mental health problems and trauma symptoms, 
notably depression and post-traumatic stress disorder 
(PTSD), related to organised violence, torture, human 
Refugees: towards better access to health-care services
an impact on mortality, and will need to be followed up 
as soon as possible with more widespread deployment of 
the vaccine in appropriate epidemiological situations if 
they show that the vaccine can be delivered, is eﬀ ective, 
and is safe. RTS,S/AS01 should not be regarded as a 
replacement for other control measures, but rather as an 
additional method to be used in areas where malaria is 
proving diﬃ  cult to control despite high levels of coverage 
with established control measures, and possibly in other 
speciﬁ c circumstances, such as elimination programmes 
and control of malaria in areas where transmission is 
very seasonal.
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